Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine H1 Revenues Rise Sharply as it Awaits IPO

NEW YORK (GenomeWeb News) – Foundation Medicine's revenues through the first half of 2013 increased 363 percent year over year, the company said in its amended Form S-1 on Friday.

The Cambridge, Mass.-based firm, which filed to go public almost three weeks ago, said that revenues through June 30 rose to $11.1 million, compared to $2.4 million during the year-ago period. Net loss for the six months increased to $17.4 million from $11.3 million a year ago.

R&D spending spiked 68 percent year over year to $11.1 million from $6.6 million, while SG&A costs more than doubled to $12.6 million from $5.0 million.

Foundation said that it had $36.0 million in cash and cash equivalents and $32.2 million in working capital as of June 30.

The company said in its Form S-1 that it plans to raise as much as $86.3 million in its initial public offering, but has not said how many shares it anticipates offering or priced its shares. It plans to list on the Nasdaq under ticker symbol "FMI".

Goldman Sachs and JP Morgan Securities are the joint book-running managers on the offering. Leerink Swann and Sanford Bernstein are also named as underwriters.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.